Ascendis Pharma company profile
Company profile
Ascendis Pharma has 1,189 employees and is headquartered in Hellerup, Denmark.
Founded in 2006, Ascendis Pharma A/S is based in Hellerup, Denmark, and develops therapies built on its TransCon technology for rare conditions with unmet medical needs in Europe, the United States and other markets. Its marketed products include SKYTROFA, prescribed to children with growth hormone shortfall, and YORVIPATH, a daily subcutaneous injection for adults with chronic hypoparathyroidism. The company also has three endocrinology rare disease candidates in clinical development and advances oncology candidates.
In the fiscal year ended December 31, 2025, revenue reached 720.1 million euros, up 98.0% on the previous year, and the company recorded a net loss of 228.0 million euros. The United States accounted for 72.9% of revenue, Europe for 16.1%, the rest of the world for 7.0% and Denmark for 1.7%. The company employs 1,189 people.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- Tuborg Boulevard 12, 2900, Hellerup
- Employees
- 1,189
- Chief executive
- Jan Mikkelsen
- Founded
- 2006
- Fiscal year
- January - December
- Listing
- ASND · NASDAQ
- Currency
- USD
- ISIN
- DK0060615755
- Website
- ascendispharma.com
Ascendis Pharma and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Ascendis PharmaASND | United States | $18.06B | 1,189 | 30.9% | 18.1 |
| ExelixisEXEL | United States | $16.37B | 1,077 | 40.2% | 20.1 |
| Jazz PharmaceuticalsJAZZ | United States | $15.5B | 2,890 | 27.4% | 71.5 |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
| BridgeBio PharmaBBIO | United States | $15.25B | 1,081 | -37.3% | — |
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
